Zymeworks Inc. (NASDAQ:ZYME) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET
Company Participants
Jack Spinks - Associate Director of Investor Relations
Ken Galbraith - Chair and CEO
Dr. Neil Josephson - CMO
Conference Call Participants
Yigal Nochomovitz - Citi
Nick Abbott - Wells Fargo
Charles Zhu - Guggenheim Securities
Stephen Willey - Stifel
Amy Li - Jefferies
Operator
Thank you for standing. This is the conference operator. Welcome to Zymeworks Second Quarter 2022 Results Conference Call and Webcast. As a reminder, all participants are in a listen-only mode and conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]
I would now like to turn the conference over to Jack Spinks, Associate Director of Investor Relations at Zymeworks. Jack, please go ahead.
Jack Spinks
Good afternoon, and welcome, everyone. My name is Jack Spinks, Associate Director of Investor Relations here at Zymeworks. Today, we will discuss our second quarter 2022 financial results as well as provide an update to our ongoing business.
Before we begin, I would like to remind you that we will be making a number of forward-looking statements during this call, including statements that relate to the implementation of our strategic priorities, development of our product candidates, related clinical trials, anticipated data presentations, potential therapeutic effects of zanidatamab and our other product candidates, our proposed redomicile transactions and the anticipated timing and benefits; expected financial performance and future financial position, the commercial potential of technology platforms and product candidates, anticipated continued receipt of revenue from existing and future partners, our preclinical pipeline, anticipated impact of the ongoing COVID-19 pandemic and our anticipated response to the same, anticipated sufficiency of cash resources and other potential sources of cash to fund our planned operations into the second half of 2023 and potentially beyond, impact of new hires, our ability to execute new collaborations and partnerships, and other information that is not historical information. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and our stage in development.For discussion of these risks and uncertainties, we refer you to our latest SEC filings is found on our website and as filed with the SEC.
In addition, please note that today's earnings call does not constitute an offer to sell or a solicitation of an offer to buy any securities or a solicitation of any vote or approval in connection with the proposed redomicile transactions. Zymeworks Delaware Inc. is filed with the SEC, registration statement on Form S-4 that includes a preliminary proxy statement/prospectus. The registration statement is not complete and will be further amended. After the registration statement has been declared effective by the SEC, the final proxy statement/prospectus we mail the Zymeworks security holders.